7 Articles found

Nanostics Inc. articles

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients

Edmonton, Alberta - Nanostics Inc., a diagnostic healthcare company that focuses on developing tests to determine a patient`s disease risk, announced today plans to develop and validate ClarityDX COVID-19; a simple blood test to predict the severity of COVID-19 disease in patients.

Nanostics, in collaboration with the Canadian BioSample Repository (CBSR) at the University of Alberta and Century Clinical Research Institute (CCRI), a Florida based clinical research company experienced a

Apr. 1, 2020

Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252

Summary

This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ng/

Jan. 2, 2020

Bio-tech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives

The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images)

A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer biopsies.

Private research company Nanostics Inc. and the University of Alberta created a simple blood test that measures cancer

Jan. 6, 2020

Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer

Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Canc

Jul. 2, 2022

Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer

Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries.
The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant p

Aug. 1, 2022